Harvard Bioscience, Inc. (HBIO) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -662K | -96K | 830K | 2.75M | 2.99M | 1.73M | -842K | -846K | 1.4M | 4.3M | 4.36M | 3.55M |
| Operating CF Margin % | -3.19% | -0.4% | 4.03% | 13.47% | 13.71% | 7.02% | -3.83% | -3.66% | 5.72% | 15.28% | 17.19% | 12.35% |
| Operating CF Growth % | -122.17% | -105.57% | 198.57% | 425.65% | 112.83% | -59.91% | -119.31% | -123.82% | -22.57% | 60.62% | 571.96% | 1969.47% |
| Net Income | -3.42M | -2.85M | -1.23M | -2.28M | -50.34M | 18K | -4.8M | -2.93M | -4.69M | -1.82M | -1.24M | -980K |
| Depreciation & Amortization | 0 | 0 | 1.32M | 1.62M | 1.66M | 1.76M | 1.81M | 1.76M | 1.85M | 1.77M | 1.78M | 1.79M |
| Stock-Based Compensation | 0 | 0 | 0 | 472K | 600K | 961K | 1.05M | 0 | 1.05M | 1.38M | 1.36M | 1.1M |
| Deferred Taxes | 0 | 0 | 20K | -50K | 0 | 724K | -768K | 229K | 178K | 244K | 6K | 0 |
| Other Non-Cash Items | 1.97M | 3.67M | 427K | 210K | 47.56M | -1.15M | 1.33M | 1.67M | 1.31M | 333K | -1.14M | 1.31M |
| Working Capital Changes | 794K | -918K | 290K | 2.79M | 3.51M | -593K | 528K | -1.58M | 1.71M | 2.39M | 3.59M | 333K |
| Change in Receivables | 1.41M | -3.96M | -210K | 1.79M | 1.44M | -2.33M | -155K | 2.75M | 704K | -941K | 1.82M | 855K |
| Change in Inventory | -1.54M | 663K | 637K | 977K | 670K | 2.35M | -668K | -1.13M | -617K | 1.35M | -225K | 690K |
| Change in Payables | 1.18M | 797K | -271K | 302K | 1.47M | -1.5M | -14K | -2.3M | 2.47M | -140K | 1.81M | 0 |
| Cash from Investing | -620K | -599K | -348K | -233K | -683K | -466K | -1.11M | 458K | -225K | -1.06M | -401K | -625K |
| Capital Expenditures | -426K | -449K | -348K | -89K | -513K | -301K | -880K | -966K | -720K | -1.06M | -401K | -517K |
| CapEx % of Revenue | 2.05% | 1.89% | 1.69% | 0.44% | 2.36% | 1.23% | 4.01% | 4.18% | 2.94% | 3.77% | 1.58% | 1.8% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -512K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -194K | -150K | 0 | -144K | -170K | -165K | -231K | 0 | 0 | 512K | 0 | -108K |
| Cash from Financing | -9K | 2.45M | -1.02M | -1.26M | -1.2M | -1.36M | 2.1M | 177K | -1.05M | -4.12M | -2.75M | -2.38M |
| Debt Issued (Net) | 0 | 1.82M | -1M | -1M | -1M | -1M | 2.25M | 0 | -1.02M | -2.25M | -2.75M | -2.7M |
| Equity Issued (Net) | 150K | 1K | 0 | 46K | -75K | 0 | 0 | 189K | 15K | 206K | 0 | -295K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -481K | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -75K | 0 | 0 | 0 | 0 | 0 | 0 | -295K |
| Other Financing | -159K | 630K | -24K | -304K | -129K | -357K | -146K | -12K | -47K | -1.59M | 0 | 620K |
| Net Change in Cash | -1.52M | 1.8M | -625K | 1.9M | 1.44M | -461K | 521K | -207K | -28K | -1.06M | 999K | 535K |
| Free Cash Flow | -1.09M | -545K | 623K | 2.52M | 2.47M | 1.26M | -1.95M | -1.66M | 683K | 3.24M | 3.96M | 3.04M |
| FCF Margin % | -5.24% | -2.3% | 3.03% | 12.33% | 11.36% | 5.13% | -8.89% | -7.2% | 2.79% | 11.52% | 15.61% | 10.55% |
| FCF Growth % | -144% | -143.29% | 131.9% | 251.56% | 262.08% | -61.17% | -149.32% | -154.83% | -56.99% | 32.65% | 1813.04% | 580.22% |
| FCF per Share | -0.24 | -0.12 | 0.14 | 0.57 | 0.56 | 0.29 | -0.45 | -0.38 | 0.16 | 0.76 | 0.93 | 0.72 |
| FCF Conversion (FCF/Net Income) | 0.19x | 0.03x | -0.67x | -1.21x | -0.06x | 95.83x | 0.18x | 0.29x | -0.30x | -2.37x | -3.52x | -3.62x |
| Interest Paid | 0 | 0 | 0 | 783K | 799K | 866K | 854K | 0 | 768K | 789K | 858K | 976K |
| Taxes Paid | 0 | 0 | 0 | 46K | 2K | 0 | 184K | 0 | 26K | 39K | 53K | 0 |